JSPR — Jasper Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP-American Express, Cintas, Kimberly-Clark
Jasper Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Jasper Therapeutics Inc expected to post a loss of $1.61 a share - Earnings Preview
Brief: Jasper Therapeutics Announces Pricing Of $50 Million Underwritten Offering Of Common Stock
Brief: Jasper Therapeutics Inc - Initial Data From Phase 1B/2A Beacon Study Expected In Mid-2024
Brief: Jasper Therapeutics, Inc. Announces Reverse Stock Split
Brief: Jasper Announces First Patient Dosed In Phase 1B/2A Clinical Study Of Briquilimab In Chronic Spontaneous Urticaria
Brief: Jasper Therapeutics Inc - Bill Lis Is Stepping Down As Chairperson
Brief: Jasper Therapeutics Announces Ind Clearance For Phase 1B/2A Study Of Subcutaneous Briquilimab In Chronic Spontaneous Urticaria
Brief: Jasper Therapeutics Appoints Herb Cross As Chief Financial Officer
Brief: Jasper Therapeutics To Present New Positive Data On Briquilimab Conditioning
Jasper Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Jasper Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Jasper Therapeutics Announces First Patient Dosed In A Phase 1 Trial Of Briquilimab In Lower-Risk Myelodysplastic Syndrome
Jasper Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Jasper Therapeutics Reports First Quarter 2023 Financial Results And Provides A Business Update
Jasper Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Jasper Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Brief: Jasper Therapeutics Appoints Daniel Adelman, M.D., As Acting Chief Medical Officer